Thiard News@F4F

@newsen.bsky.social

7 months ago

AliveDx Submits 510(k) Notification to the FDA for Innovative Vasculitis Test AliveDx has announced the submission of its 510(k) notification to the FDA for the MosaiQ AiPlex® Vasculitis test, enhancing diagnostic capabilities for autoimmune conditions.

AliveDx Submits 510(k) Notification to the FDA for Innovative Vasculitis Test #USA #AliveDx #Eysins #MosaiQ_AiPlex #Vasculitis_Test

Thiard News@F4F

@newsen.bsky.social

7 months ago

AliveDx Submits 510(k) Notification for Innovative MosaiQ AiPlex® Vasculitis Test to the FDA AliveDx has announced the submission of a 510(k) premarket notification to the FDA for its MosaiQ AiPlex® Vasculitis test, aimed at enhancing autoimmune disease diagnostics.

AliveDx Submits 510(k) Notification for Innovative MosaiQ AiPlex® Vasculitis Test to the FDA #USA #AliveDx #MosaiQ #Eysins #Vasculitis

Thiard News@F4F

@newsen.bsky.social

7 months ago

AliveDx Submits 510(k) Application for the MosaiQ AiPlex® Vasculitis Assay to FDA AliveDx has announced the submission of a 510(k) application to the FDA for its innovative MosaiQ AiPlex® Vasculitis assay aimed at improving diagnoses of autoimmune diseases.

AliveDx Submits 510(k) Application for the MosaiQ AiPlex® Vasculitis Assay to FDA #USA #FDA_Approval #AliveDx #Eysins #MosaiQ_AiPlex

Thiard News@F4F

@newsen.bsky.social

7 months ago

AliveDx Takes Significant Steps with FDA Submission for MosaiQ AiPlex® Vasculitis Assay AliveDx has officially submitted its MosaiQ AiPlex® Vasculitis assay for FDA clearance, aspiring to enhance diagnostic solutions for autoimmune vasculitis, improving patient outcomes.

AliveDx Takes Significant Steps with FDA Submission for MosaiQ AiPlex® Vasculitis Assay #USA #AliveDx #Eysins #MosaiQ_AiPlex #FDA_Submission

Thiard News@F4F

@newsen.bsky.social

7 months ago

AliveDx Secures FDA Registration for MosaiQ® Multiplex Testing Instrument AliveDx has announced its MosaiQ® instrument is now registered as a Class II device with the FDA, enhancing diagnostic capabilities for autoimmune diseases and allergies in the US.

AliveDx Secures FDA Registration for MosaiQ® Multiplex Testing Instrument #USA #FDA_Approval #AliveDx #MosaiQ #Eysins

Thiard News@F4F

@newsen.bsky.social

7 months ago

AliveDx Receives FDA Approval for MosaiQ Multiplex Testing Device Targeting Autoimmune Diseases and Allergies AliveDx's MosaiQ device has been granted Class II FDA approval, allowing multiplex testing for autoimmune diseases and allergies, revolutionizing patient diagnostics.

AliveDx Receives FDA Approval for MosaiQ Multiplex Testing Device Targeting Autoimmune Diseases and Allergies #USA #FDA_Approval #AliveDx #MosaiQ #Eysins

Thiard News@F4F

@newsen.bsky.social

8 months ago

MosaiQ AiPlex® Vasculitis Test Now Available for Clinical Use in Europe The MosaiQ AiPlex® Vasculitis test is now clinically available in the EU and other CE-mark accepted countries, revolutionizing autoimmune diagnostics.

MosaiQ AiPlex® Vasculitis Test Now Available for Clinical Use in Europe #Switzerland #AliveDx #Eysins #MosaiQ_AiPlex #Vasculitis

Thiard News@F4F

@newsen.bsky.social

8 months ago

AliveDx Launches MosaiQ AiPlex® Vasculitis Assay for Clinical Use in Europe AliveDx has announced the clinical availability of its MosaiQ AiPlex® Vasculitis assay across Europe, streamlining autoimmune diagnostics and enhancing patient care.

AliveDx Launches MosaiQ AiPlex® Vasculitis Assay for Clinical Use in Europe #None #AliveDx #MosaiQ_AiPlex #Vasculitis

Thiard News@F4F

@newsen.bsky.social

8 months ago

AliveDx Launches Innovative MosaiQ AiPlex Vasculitis Assay for Clinical Use in Europe AliveDx announces the successful launch of its MosaiQ AiPlex Vasculitis assay, which is now available for clinical utilization across Europe and CE-marking-approved nations.

AliveDx Launches Innovative MosaiQ AiPlex Vasculitis Assay for Clinical Use in Europe #Switzerland #AliveDx #MosaiQ #Eysins #Vasculitis

Thiard News@F4F

@newsen.bsky.social

8 months ago

AliveDx Launches MosaiQ AiPlex® Vasculitis Assay for Clinical Use in Europe AliveDx has received IVDR-CE Mark approval for its MosaiQ AiPlex® Vasculitis assay, facilitating faster diagnosis of autoimmune vasculitis across Europe.

AliveDx Launches MosaiQ AiPlex® Vasculitis Assay for Clinical Use in Europe #Switzerland #AliveDx #MosaiQ #Eysins #Vasculitis

Thiard News@F4F

@newsen.bsky.social

8 months ago

AliveDx Launches Innovative MosaiQ AiPlex® Vasculitis Assay in Europe AliveDx has introduced the MosaiQ AiPlex® Vasculitis assay for clinical use in Europe, streamlining diagnosis and improving outcomes for autoimmune conditions.

AliveDx Launches Innovative MosaiQ AiPlex® Vasculitis Assay in Europe #None #AliveDx #MosaiQ_AiPlex #Vasculitis

Thiard News@F4F

@newsen.bsky.social

1 year ago

AliveDx Seeks FDA Approval for Revolutionary Multiplex Biochip Technology AliveDx has taken a significant step by submitting a 510(k) premarket notification to the FDA for its innovative multiplex biochip MosaiQ AiPlex® CTDplus. This technology aims to improve autoimmune disease diagnostics.

AliveDx Seeks FDA Approval for Revolutionary Multiplex Biochip Technology #USA #AliveDx #Eysins #MosaiQ_AiPlex #FDA_510(k)

Thiard News@F4F

@newsen.bsky.social

1 year ago

AliveDx Submits 510(k) Application for MosaiQ AiPlex® Multiplex Test for Systemic Connective Tissue Diseases AliveDx has submitted a 510(k) premarket notification to the FDA for its MosaiQ AiPlex® multiplex microarray aimed at diagnosing systemic connective tissue diseases efficiently.

AliveDx Submits 510(k) Application for MosaiQ AiPlex® Multiplex Test for Systemic Connective Tissue Diseases #AliveDx #MosaiQ #AiPlex

Thiard News@F4F

@newsen.bsky.social

1 year ago

AliveDx Submits 510(k) Application for MosaiQ AiPlex CTDplus Microarray to FDA AliveDx has filed a 510(k) application for the innovative MosaiQ AiPlex CTDplus microarray, targeting advancements in connective tissue disease diagnostics.

AliveDx Submits 510(k) Application for MosaiQ AiPlex CTDplus Microarray to FDA #USA #AliveDx #Eysins #MosaiQ_AiPlex #CTDplus

Thiard News@F4F

@newsen.bsky.social

1 year ago

AliveDx Submits 510(k) Application for Advanced CTD Multiplex Microarray to the US FDA AliveDx has announced the submission of a 510(k) premarket notification to the FDA for its groundbreaking MosaiQ AiPlex CTDplus multiplex microarray, aimed at improving autoimmune disease diagnoses.

AliveDx Submits 510(k) Application for Advanced CTD Multiplex Microarray to the US FDA #USA #AliveDx #Eysins #MosaiQ_AiPlex #FDA_510(k)

Thiard News@F4F

@newsen.bsky.social

1 year ago

AliveDx Submits Notice to FDA for Advanced Celiac Disease Testing Solution AliveDx has announced the submission of its 510(k) premarket notification to the FDA for the MosaiQ AiPlex® Celiac Disease microarray, enhancing diagnosis speed.

AliveDx Submits Notice to FDA for Advanced Celiac Disease Testing Solution #USA #AliveDx #MosaiQ_AiPlex #Celiac_Disease #Eysins,_Switzerland

Thiard News@F4F

@newsen.bsky.social

1 year ago

AliveDx's Innovative MosaiQ AiPlex Aims to Transform Celiac Disease Diagnosis in the U.S. AliveDx has submitted a 510(k) application to the FDA for its MosaiQ AiPlex microarray, promising faster, accurate diagnoses for celiac disease.

AliveDx's Innovative MosaiQ AiPlex Aims to Transform Celiac Disease Diagnosis in the U.S. #USA #AliveDx #Eysins #MosaiQ_AiPlex #Celiac_Disease

Thiard News@F4F

@newsen.bsky.social

1 year ago

AliveDx Files 510(k) Submission with FDA for Innovative MosaiQ AiPlex® Celiac Disease Test AliveDx has officially submitted a 510(k) premarket notification to the FDA for its groundbreaking MosaiQ AiPlex® Celiac Disease microarray, promising rapid and accurate diagnoses.

AliveDx Files 510(k) Submission with FDA for Innovative MosaiQ AiPlex® Celiac Disease Test #USA #AliveDx #Eysins #MosaiQ_AiPlex #Celiac_Disease

Thiard News@F4F

@newsen.bsky.social

1 year ago

AliveDx Submits 510(k) Application for MosaiQ AiPlex® Celiac Disease Test to FDA AliveDx has announced the submission of a 510(k) premarket notification to the FDA for their MosaiQ AiPlex® Celiac Disease test, aiming to enhance diagnostic efficiency.

AliveDx Submits 510(k) Application for MosaiQ AiPlex® Celiac Disease Test to FDA #USA #AliveDx #Eysins #MosaiQ_AiPlex #Celiac_Disease

Thiard News@F4F

@newsen.bsky.social

1 year ago

AliveDx Submits FDA 510(k) for MosaiQ AiPlex® Celiac Disease Test to Revolutionize Diagnosis AliveDx has submitted a 510(k) notification to the FDA for MosaiQ AiPlex® Celiac Disease microarray, promising faster, more accurate diagnostics.

AliveDx Submits FDA 510(k) for MosaiQ AiPlex® Celiac Disease Test to Revolutionize Diagnosis #USA #AliveDx #Eysins #MosaiQ_AiPlex #Celiac_Disease

Thiard News@F4F

@newsen.bsky.social

1 year ago

AliveDx Introduces Cutting-Edge MosaiQ AiPlex Multiplex Assay for Autoimmune Disease Diagnosis AliveDx proudly announces the IVDR-CE mark for its MosaiQ AiPlex CTDplus assay, enhancing diagnostic efficiency for autoimmune diseases.

AliveDx Introduces Cutting-Edge MosaiQ AiPlex Multiplex Assay for Autoimmune Disease Diagnosis #Switzerland #AliveDx #MosaiQ #Eysins #Autoimmune

Thiard News@F4F

@newsen.bsky.social

1 year ago

AliveDx Launches Advanced MosaiQ AiPlex® CTDplus Test for Autoimmune Diseases AliveDx announces the IVDR-CE marking for its MosaiQ AiPlex® CTDplus multiplex test, enhancing the diagnosis of systemic autoimmune diseases and lab workflows.

AliveDx Launches Advanced MosaiQ AiPlex® CTDplus Test for Autoimmune Diseases #Switzerland #AliveDx #MosaiQ #Eysins #AiPlex_CTDplus

Thiard News@F4F

@newsen.bsky.social

1 year ago

AliveDx Introduces New IVDR-CE Certified Diagnostic Tool for Autoimmune Diseases AliveDx has launched the MosaiQ AiPlex CTDplus, an IVDR-CE certified multiplex assay aimed at enhancing the diagnosis of systemic autoimmune diseases and improving lab efficiency.

AliveDx Introduces New IVDR-CE Certified Diagnostic Tool for Autoimmune Diseases #Switzerland #AliveDx #MosaiQ #Eysins #Autoimmune

Thiard News@F4F

@newsen.bsky.social

1 year ago

AliveDx Expands Product Range for Autoimmune Diseases with New Multiplex Test for Systemic Rheumatic Diseases AliveDx has introduced its IVDR-CE marked MosaiQ AiPlex® CTDplus multiplex test to diagnose systemic autoimmune rheumatic diseases efficiently.

AliveDx Expands Product Range for Autoimmune Diseases with New Multiplex Test for Systemic Rheumatic Diseases #Switzerland #AliveDx #MosaiQ #Eysins #AiPlex_CTDplus

Thiard News@F4F

@newsen.bsky.social

1 year ago

AliveDx Launches Innovative Multiplex Assay to Enhance Autoimmune Diagnostics AliveDx's new MosaiQ AiPlex CTDplus assay receives IVDR-CE mark, streamlining diagnostics for autoimmune rheumatic diseases across laboratories.

AliveDx Launches Innovative Multiplex Assay to Enhance Autoimmune Diagnostics #Switzerland #Autoimmune_Diseases #AliveDx #MosaiQ #Eysins